drugset / Trial / NCT06558656

Effect of Food of NTQ5082 in Healthy Subjects

NCT06558656

Phase 1 Not yet recruiting 12 enrolled Nanjing Chia-tai Tianqing Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

NTQ5082 capsule is a small molecule CFB factor inhibitor. The study is a randomized, open label, two sequence, two period, double crossover-design phase 1 clinical trial to evaluate the food effect on PK after a single oral administration of NTQ5082 capsules and the safety and tolerability of single oral administration of NTQ5082 capsules on an empty stomach (i.e, fasting) as well as after a meal (i.e. fed) in healthy subjects

Timeline

Start
2024-08
Primary completion
2024-12
Completion
2025-02

Drugs

EvaluationDrugModalityDoseRoute
Subject NTQ5082 Small molecule Oral

Indications